Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 27, 2020 16:30 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results

-Dosing re-initiated in clinical trials of CTX001™ for patients with severe hemoglobinopathies- - CTX001 has received orphan drug designation from the U.S. FDA for sickle cell disease (SCD)- ...
June 30, 2020 21:29 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares

ZUG, Switzerland and CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for...
June 29, 2020 16:01 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Announces Proposed Offering of Common Shares

ZUG, Switzerland and CAMBRIDGE, Mass., June 29, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for...
June 25, 2020 08:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility

-State-of-the-art facility to be located in Framingham, Massachusetts- -New facility intended to support clinical and commercial production of investigational cell therapies- ZUG, Switzerland and...
June 12, 2020 02:30 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress

-Beta thalassemia: Two patients are transfusion independent at 5 and 15 months after CTX001 infusion; data demonstrate clinical proof-of-concept for CTX001 in transfusion-dependent beta thalassemia- ...
May 26, 2020 08:30 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
May 15, 2020 08:30 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting

ZUG, Switzerland and CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
May 14, 2020 09:02 ET | Source: CRISPR Therapeutics AG

New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress

ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, May 14, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that new...
May 11, 2020 09:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies

ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, May 11, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the...
May 07, 2020 08:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference

ZUG, Switzerland and CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...